BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE - Generic Drug Details

What are the generic drug sources for bupivacaine hydrochloride; epinephrine bitartrate and what is the scope of freedom to operate?

Bupivacaine hydrochloride; epinephrine bitartrate is the generic ingredient in five branded drugs marketed by Hospira, Fresenius Kabi Usa, and Septodont, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Five suppliers are listed for this compound.

Summary for BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

US Patents:	0
Tradenames:	5
Applicants:	3
NDAs:	7
Finished Product Suppliers / Packagers:	5
Clinical Trials:	2
DailyMed Link:	BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE at DailyMed

Recent Clinical Trials for BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sunnybrook Health Sciences Centre	N/A
Cosmozone Dental Clinic	N/A

See all BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE clinical trials

Pharmacology for BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

Drug Class	Amide Local Anesthetic Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Local Anesthesia

Anatomical Therapeutic Chemical (ATC) Classes for BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

A01AD	Other agents for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

B02BC	Local hemostatics
B02B	VITAMIN K AND OTHER HEMOSTATICS
B02	ANTIHEMORRHAGICS
B	Blood and blood forming organs

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

N01BB	Amides
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03AA	Alpha- and beta-adrenoreceptor agonists
R03A	ADRENERGICS, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01EA	Sympathomimetics in glaucoma therapy
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	SENSORCAINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	070967-001	Oct 13, 1987	AP	RX	No	No
Hospira	BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022046-001	Jul 13, 1983		DISCN	Yes	No
Fresenius Kabi Usa	SENSORCAINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	070968-001	Oct 13, 1987	AP	RX	No	No
Fresenius Kabi Usa	SENSORCAINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	018304-004	Sep 2, 1983	AP	RX	Yes	No

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE Market Analysis and Financial Projection

Last updated: February 15, 2026

What Is the Market Size and Demand for Bupivacaine Hydrochloride with Epinephrine Bitartrate?

The combination of bupivacaine hydrochloride with epinephrine bitartrate is primarily used for local anesthesia in surgical procedures. As of 2023, the global local anesthetics market was valued at approximately $3.4 billion, with an annual growth rate of 4.2% projected through 2030[1].

Bupivacaine-based products constitute a significant portion, driven by their duration of action. The inclusion of epinephrine extends anesthetic effects and reduces systemic absorption, thereby increasing safety and efficacy. North America and Europe account for roughly 60% of the market, with the U.S. leading in consumption, due to high procedural volumes. Growth in emerging markets, such as China and India, is also notable, driven by expanding healthcare infrastructure.

How Are Regulatory Policies Affecting Market Access and Penetration?

The U.S. Food and Drug Administration (FDA) regulates bupivacaine formulations as prescription drugs. The FDA approval process emphasizes demonstrating safety, efficacy, and manufacturing quality. New formulations combining bupivacaine and epinephrine require clinical data to meet these standards, which can extend development timelines.

The European Medicines Agency (EMA) similarly oversees approval within Europe under the centralized procedure. Patent protections and market exclusivities, varying across jurisdictions, influence market entry and pricing strategies. For example, patents on specific formulations or delivery systems protect incumbent manufacturers for approximately 10-15 years post-approval.

What Are the Patent and Competition Landscapes?

Brand-name formulations like Marcaine (Pfizer) dominate the market, with patent protections expiring between 2024 and 2028[2]. Once patents expire, generic versions enter, causing price reductions typically between 20-50%.

Enterprises developing novel delivery systems (e.g., liposomal formulations or extended-release versions) can secure new patents, extending their market exclusivity. Competition is fierce among manufacturers of generic bupivacaine with epinephrine in sterile solutions, with over 50 approved products worldwide.

What Are the Financial Trends and Forecasts?

Leading companies like Pfizer, Hikma, and Mylan generate annual revenues exceeding $300 million from bupivacaine-based products. Price points for branded formulations hover around $10-15 per dose, with generics available for $4-8.

Market growth accelerates in emerging economies with expanding elective and emergency procedures. A forecast from GlobalData expects the market for bupivacaine with epinephrine to grow at 4-6% CAGR from 2023 to 2028, driven by increased procedural volume and new product launches.

What Key Developments Could Influence the Market in Coming Years?

• Generic patent expirations: Expected between 2024-2028, opening opportunities for lower-cost options.
• Novel formulations: Liposomal or extended-release versions, offering longer anesthetic durations, are under clinical evaluation.
• Regulatory changes: Evolving safety standards, particularly concerning epinephrine dosages, could influence formulation requirements.
• Market entry of biosimilars or biologic adjuncts: Though less common for local anesthetics, innovations could influence pricing and usage.

Summary Table: Market Data Snapshot

Aspect	Data
Global market size (2023)	$3.4 billion
CAGR (2023-2030)	4.2%
Leading regional markets	North America (35%), Europe (25%)
Patent expiration timeframe	2024–2028
Key price per dose (branded)	$10–$15
Key price per dose (generic)	$4–$8

Key Takeaways

• The market for bupivacaine hydrochloride with epinephrine bitartrate remains robust, with steady growth driven by procedural volume increases.
• Patent expirations create opportunities for generics, leading to price erosion and increased competition.
• Regulatory frameworks favor product approval consistency but pose barriers for novel formulations.
• Innovation in delivery systems could extend product lifecycle and market share.
• Emerging markets are becoming significant growth points, with increasing healthcare infrastructure and procedural volumes.

FAQs

1. How do patent expirations impact the availability of generic formulations?
Patent expirations allow generic manufacturers to enter the market, reducing prices and increasing access, typically resulting in a 20-50% price decrease.

2. What regulatory hurdles may slow new formulations of bupivacaine with epinephrine?
New formulations must demonstrate safety and efficacy through clinical trials, and navigate healthcare authority approval processes, which may include additional safety data for epinephrine doses.

3. Are there notable differences between branded and generic products?
Branded products may have proprietary delivery systems or formulations, while generics match the active ingredients but may differ in excipients or delivery methods, potentially affecting duration and onset.

4. What innovations could extend the market life of existing bupivacaine formulations?
Extended-release formulations and liposomal delivery systems can offer longer-lasting anesthesia, creating opportunities for patent protection and higher pricing.

5. How significant is the role of emerging markets in future growth?
Emerging economies like China and India are increasing procedural volumes and healthcare investments, positioning them as key growth regions for both brand and generic products.

---

References

[1] MarketsandMarkets, "Local Anesthetics Market Size, Share & Trends," 2022.
[2] U.S. Patent and Trademark Office, Patent Expiration List, 2023.